Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma

P. Bidoli, S. Spinazze, A. Santoro, P. Casali, A. V. Bedini, A. Guzzon

Research output: Contribution to journalArticle

Abstract

Twenty-five patients with advanced non-small-cell lung carcinoma (NSCLC) were treated with a multidrug regimen (CIV) consisting of ifosfamide (IFX), cisplatin (CDDP), and etoposide (VP-16). Twenty-four patients were evaluable for response. An objective response was detected in eight cases (33%), including one case with complete tumor response. Median duration of response was 31 weeks, and median overall survival 46 weeks, with no significant difference between responders and nonresponders. Myelosuppression and gastrointestinal side effects represented the main toxic manifestations; a toxic death and an ischemic cardiac episode were also observed. CIV seems a moderately effective regimen in NSCLC, but unlikely to provide an advantage over the widely employed two-drug combination of CDDP and VP-16.

Original languageEnglish
Pages (from-to)424-426
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number5
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma'. Together they form a unique fingerprint.

  • Cite this